NSTI Nanotech 2009

2009 Symposium on

Nanotechnology for Cancer Prevention, Diagnosis and Treatment

CancerNano 2009

May 3 - 7, 2009
George R. Brown Convention Center
Houston, Texas, U.S.A

Symposium sponsors

National Cancer Institute National Institutes of Health

Symposium Co-Chairs

Mansoor Amiji Mansoor Amiji
Department of Pharmaceutical Sciences,
Northeastern University
Vladimir Torchilin Vladimir Torchilin
Bouvé College of Health Sciences,
Northeastern University

Confirmed Invited Speakers

Mauro Ferrari Nanotechnology Opportunities in Cancer
Mauro Ferrari
President, Alliance for NanoHealth
Professor, University of Texas Health Science Center at Houston

Steven A. Curley Thermal Therapy for Cancer
Steven A. Curley
MD, University of Texas MD Anderson Cancer Center
Jim Klostergaard Enhancing Cancer Therapy with Nano-Delivery Systems
Jim Klostergaard
Professor, University of Texas MD Anderson Cancer Center

John Mendelsohn John Mendelsohn
The University of Texas MD Anderson Cancer Center
Piotr Grodzinski Clinical Translation of Cancer Nanotechnology
Piotr Grodzinski

Director, Nanotechnology for Cancer Programs, NCI Alliance for Nanotechnology in Cancer, National Institutes of Health (NIH)

Wendy Sanhai Food and Drug Administration Perspective
Wendy Sanhai

Rebecca Richards-Kortum Early Cancer Detection with Nanotechnology
Rebecca Richards-Kortum
Stanley C. Moore Professor of Bioengineering, Rice University

 Renata Pasqualini Cancer Target Identification and Validation
Renata Pasqualini
MD, University of Texas MD Anderson Cancer Center

Ananth Annapragada Targeted Nanoparticles for Cancer Therapy
Ananth Annapragada
Associate Professor, University of Texas Health Science Center at Houston

Scott E. McNeil Lessons Learned in Cancer Nanotechnology
Scott E. McNeil

Director, Nanotechnology Characterization Laboratory, National Cancer Institute

J. Donald Payne J. Donald Payne
President and CEO, Director Nanospectra Bioscience, Inc


NSTI is proud to collaborate with the National Cancer Institute (NCI) in presenting a Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.

Towards the end of eliminating suffering and death from cancer, the National Cancer Institute is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, image and treat cancer. The NCI-NSTI Nanotechnology for Cancer Special Symposium will run in parallel with the Nanotech 2009 and the BioNano 2009 providing a unique multidisciplinary environment directed towards addressing the challenges of cancer research and treatment.

Video Journey Into Nanotechnology

Watch Video Journey Into Nanotechnology (provided courtesy of NCI)


Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

Topics and Applications

  • Science and technologies for cancer diagnostic and imaging techniques using nanoparticles as reporter platforms and contrast enhancing agents;
  • Bionalaytical nanotechnology for detection of biomarkers
  • Nanoparticle platforms polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, magnetic nanoparticles, and self-assembling nanosystems;
  • Synthetic chemistry required to design and optimize new strategies for nanoparticle preparation and functionalization;
  • Therapeutic targeted and intra-cellular drug and gene delivery using nanocarriers;
  • Nanoparticles for delivery of electromagnetic energy for hyperthermia and thermal ablation of tumors;
  • Theoretical modeling of nanoparticle processes in biological and medical environments, and of drug and gene delivery;
  • Combination therapies (drug and energy delivery) using nanoparticles
  • Clinical diagnosis and therapy of prostate, breast, and liver cancer.



Journal Submissions

Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine)

Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine)

Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine) is a newly established, international, peer-reviewed journal published quarterly. Nanomedicine publishes basic, clinical, and engineering research in the innovative field of nanomedicine. Article categories include basic nanomedicine, diagnostic nanomedicine, experimental nanomedicine, clinical nanomedicine, and engineering nanomedicine, pharmacological nanomedicine.

For consideration into the Nanomedicine: Nanotechnology, Biology and Medicine journal please select the “Submit to Nanomedicine: Nanotechnology, Biology and Medicine” button during the on-line submission procedure. You may only select a single journal during the submission process.

Journal of Nanoparticle Research

Journal of Nanoparticle Research

Selected Nanotech Proceedings papers will be reviewed and invited into a Special Issue of Journal of Nanoparticle Research. The journal disseminates knowledge of the physical, chemical and biological phenomena and processes in nanoscale structures.

For consideration into this Special Issue of Journal of Nanoparticle Research, please select the “Submit to Journal of Nanoparticle Research” button during the on-line submission procedure. You may only select a single journal during the submission process.


Program | Tracks | Symposia | Workshops | Exhibitor | Press |
Venue | News | Subscribe | Contact | Site Map
© Copyright 2008 Nano Science and Technology Institute. All Rights Reserved.